Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.

Abstract

Correction to: Genetics in Medicine 2022; https://doi.org/10.1016/j.gim.2021.08.016In the article “Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants” by Li H et al (Genet Med 2022;24:119-129), the affiliations for authors Siranoush Manoukian and Barbara Pasini were not listed correctly. The affiliations have been corrected online and can be accessed at https://doi.org/10.1016/j.gim.2021.08.016. Correction to: Genetics in Medicine 2022; https://doi.org/10.1016/j.gim.2021.08.016 In the article “Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants” by Li H et al (Genet Med 2022;24:119-129), the affiliations for authors Siranoush Manoukian and Barbara Pasini were not listed correctly. The affiliations have been corrected online and can be accessed at https://doi.org/10.1016/j.gim.2021.08.016. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsGenetics in MedicineVol. 24Issue 1PreviewGermline genetic testing for BRCA1 and BRCA2 variants has been a part of clinical practice for >2 decades. However, no studies have compared the cancer risks associated with missense pathogenic variants (PVs) with those associated with protein truncating (PTC) variants. Full-Text PDF